Curiox Biosystems - Public Comps and Valuation Multiples

Curiox Biosystems Overview

About Curiox Biosystems

Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.

Founded

2018

HQ

Employees

n/a

Website

curiox.co.kr

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$254M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Curiox Biosystems Financials

Curiox Biosystems has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Curiox Biosystems achieved revenue of $3.1M and an EBITDA of -$3.2M.

Curiox Biosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Curiox Biosystems valuation multiples based on analyst estimates

Curiox Biosystems P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$4.6M	$3.1M	XXX	XXX	XXX
Gross Profit	$3.2M	$2.6M	XXX	XXX	XXX
Gross Margin	70%	83%	XXX	XXX	XXX
EBITDA	-$5.6M	-$3.2M	XXX	XXX	XXX
EBITDA Margin	-121%	-103%	XXX	XXX	XXX
Net Profit	-$7.8M	-$6.8M	XXX	XXX	XXX
Net Margin	-169%	-219%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Curiox Biosystems Stock Performance

As of April 25, 2025, Curiox Biosystems's stock price is KRW 24400 (or $17).

Curiox Biosystems has current market cap of KRW 393B (or $268M), and EV of KRW 373B (or $254M).

See Curiox Biosystems trading valuation data

Curiox Biosystems Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$254M	$268M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Curiox Biosystems Valuation Multiples

As of April 25, 2025, Curiox Biosystems has market cap of $268M and EV of $254M.

Curiox Biosystems's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Curiox Biosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Curiox Biosystems and 10K+ public comps

Curiox Biosystems Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$254M	XXX	XXX	XXX
EV/Revenue	81.2x	XXX	XXX	XXX
EV/EBITDA	-79.0x	XXX	XXX	XXX
P/E	-48.6x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-37.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Curiox Biosystems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Curiox Biosystems Valuation Multiples

Curiox Biosystems's NTM/LTM revenue growth is n/a

Curiox Biosystems's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Curiox Biosystems's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Curiox Biosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Curiox Biosystems and other 10K+ public comps

Curiox Biosystems Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-32%	XXX	XXX	XXX	XXX
EBITDA Margin	-103%	XXX	XXX	XXX	XXX
EBITDA Growth	-43%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	34%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	36%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	55%	XXX	XXX	XXX	XXX
Opex to Revenue	347%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry